{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:19:27Z","timestamp":1783473567959,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-047"],"award-info":[{"award-number":["2022-PUMCH-B-047"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02174-8","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:25:22Z","timestamp":1778682322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimized interpretation of p53 immunohistochemistry for prediction of TP53 mutations and patient survival in DLBCL"],"prefix":"10.1007","volume":"26","author":[{"given":"Jing","family":"Ruan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congwei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"2174_CR1","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138.","journal-title":"Blood"},{"key":"2174_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ajh.26151","volume":"96","author":"S Susanibar-Adaniya","year":"2021","unstructured":"Susanibar-Adaniya S, Barta SK. 2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96:617\u201329.","journal-title":"Am J Hematol"},{"key":"2174_CR3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.V106.11.492.492","volume":"106","author":"LH Sehn","year":"2005","unstructured":"Sehn LH, Chhanabhai M, Fitzgerald C, et al. Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma (DLBCL) treated with Rituximab and CHOP (R-CHOP). Blood. 2005;106:492\u2013492.","journal-title":"Blood"},{"key":"2174_CR4","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.2019002729","volume":"135","author":"AS Ruppert","year":"2020","unstructured":"Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135:2041\u20138.","journal-title":"Blood"},{"key":"2174_CR5","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a001016","volume":"2","author":"AI Robles","year":"2010","unstructured":"Robles AI, Harris CC. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol. 2010;2:a001016.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2174_CR6","doi-asserted-by":"publisher","first-page":"7243","DOI":"10.1182\/bloodadvances.2023011384","volume":"7","author":"DJ Landsburg","year":"2023","unstructured":"Landsburg DJ, Morrissette JJ, Nasta SD, Barta SK, Schuster SJ, Svoboda J, et al. TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era. Blood Adv. 2023;7:7243\u201353.","journal-title":"Blood Adv"},{"key":"2174_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.critrevonc.2015.08.006","volume":"97","author":"T-X Lu","year":"2016","unstructured":"Lu T-X, Young KH, Xu W, Li J-Y. TP53 dysfunction in diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2016;97:47\u201355.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2174_CR8","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.62347\/LHIO8294","volume":"14","author":"W Wen","year":"2024","unstructured":"Wen W, Zhang W-L, Tan R, Zhong T-T, Zhang M-R, Fang X-S. Progress in deciphering the role of p53 in diffuse large B-cell lymphoma: mechanisms and therapeutic targets. Am J Cancer Res. 2024;14:3280\u201393.","journal-title":"Am J Cancer Res"},{"key":"2174_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01358-y","volume":"8","author":"R Shen","year":"2023","unstructured":"Shen R, Fu D, Dong L, Zhang M-C, Shi Q, Shi Z-Y, et al. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma. Signal Transduct Target Ther. 2023;8:145.","journal-title":"Signal Transduct Target Ther"},{"key":"2174_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/cjp2.223","volume":"7","author":"A Bouroumeau","year":"2021","unstructured":"Bouroumeau A, Bussot L, Bonnefoix T, et al. c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma. J Pathol Clin Res. 2021;7:604\u201315.","journal-title":"J Pathol Clin Res"},{"key":"2174_CR11","first-page":"602","volume":"118","author":"M Baran","year":"2017","unstructured":"Baran M, Canoz O, Altuntas H, Sivgin S, Cetin M, Yay A, et al. Immunohistochemical investigation of P16, P53 and Ki-67\u2019s prognostic values in diffuse large B-Cell lymphomas. Bratisl Lek Listy. 2017;118:602\u20138.","journal-title":"Bratisl Lek Listy"},{"key":"2174_CR12","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s12253-019-00674-5","volume":"26","author":"AH Zaky","year":"2020","unstructured":"Zaky AH, Elsers D, Bakry R, Abdelwanis M, Nabih O, Hafez R, et al. Prognostic value of accumulative expression of COX-2 and p53 in small and diffuse large B cell lymphoma. Pathol Oncol Res. 2020;26:1183\u201390.","journal-title":"Pathol Oncol Res"},{"key":"2174_CR13","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.3390\/curroncol30020102","volume":"30","author":"JCA Moreno","year":"2023","unstructured":"Moreno JCA, Bahmad HF, Aljamal AA, Delgado R, Salami A, Guillot C, et al. Prognostic significance of p53 and p63 in diffuse large B-Cell lymphoma: a single-institution experience. Curr Oncol. 2023;30:1314\u201331.","journal-title":"Curr Oncol"},{"key":"2174_CR14","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/670358","author":"P Rujirojindakul","year":"2011","unstructured":"Rujirojindakul P, Aiempanakit K, Kayasut K, Lekhakula A, Sriplung H. No prognostic impact of p53 and P-Glycoprotein expression in patients with diffuse large B-Cell lymphoma. ISRN Oncol. 2011. https:\/\/doi.org\/10.5402\/2011\/670358.","journal-title":"ISRN Oncol"},{"issue":"Suppl 1","key":"2174_CR15","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","volume":"38","author":"M K\u00f6bel","year":"2019","unstructured":"K\u00f6bel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG. Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility. Int J Gynecol Pathol. 2019;38(Suppl 1):S123\u201331.","journal-title":"Int J Gynecol Pathol"},{"key":"2174_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/cjp2.53","volume":"2","author":"M K\u00f6bel","year":"2016","unstructured":"K\u00f6bel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res. 2016;2:247\u201358.","journal-title":"J Pathol Clin Res"},{"key":"2174_CR17","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","volume":"28","author":"A Younes","year":"2017","unstructured":"Younes A, Hilden P, Coiffier B, et al. International working group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017;28:1436\u201347.","journal-title":"Ann Oncol"},{"key":"2174_CR18","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ajhg.2016.08.016","volume":"99","author":"NM Ioannidis","year":"2016","unstructured":"Ioannidis NM, Rothstein JH, Pejaver V, et al. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet. 2016;99:877\u201385.","journal-title":"Am J Hum Genet"},{"key":"2174_CR19","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","volume":"50","author":"AO Giacomelli","year":"2018","unstructured":"Giacomelli AO, Yang X, Lintner RE, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50:1381\u20137.","journal-title":"Nat Genet"},{"key":"2174_CR20","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1007\/s00277-023-05420-1","volume":"102","author":"OAEH Ebid","year":"2023","unstructured":"Ebid OAEH, Ezz El Arab LR, Saad AS, Ezz El Din M, Mostafa N, Swellam M. Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma. Ann Hematol. 2023;102:3477\u201388.","journal-title":"Ann Hematol"},{"key":"2174_CR21","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1111\/bjh.17971","volume":"196","author":"A Chiappella","year":"2022","unstructured":"Chiappella A, Diop F, Agostinelli C, et al. Prognostic impact of TP53 mutation in newly diagnosed diffuse large b-cell lymphoma patients treated in the FIL-DLCL04 trial. Br J Haematol. 2022;196:1184\u201393.","journal-title":"Br J Haematol"},{"key":"2174_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01765-w","volume":"22","author":"K-X Du","year":"2024","unstructured":"Du K-X, Wu Y-F, Hua W, et al. Identify truly high-risk TP53-mutated diffuse large b cell lymphoma patients and explore the underlying biological mechanisms. Cell Commun Signal. 2024;22:401.","journal-title":"Cell Commun Signal"},{"key":"2174_CR23","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1182\/blood-2013-04-493486","volume":"121","author":"F Jardin","year":"2013","unstructured":"Jardin F, Coiffier B. TP53 and outcome in DLBCL: not only the coding region. Blood. 2013;121:4433\u20134.","journal-title":"Blood"},{"key":"2174_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33230-3","volume":"8","author":"P Peroja","year":"2018","unstructured":"Peroja P, Pedersen M, Mantere T, et al. Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP. Sci Rep. 2018;8:14814.","journal-title":"Sci Rep"},{"key":"2174_CR25","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1182\/blood-2008-01-129783","volume":"112","author":"KH Young","year":"2008","unstructured":"Young KH, Leroy K, M\u00f8ller MB, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large b-cell lymphoma: an international collaborative study. Blood. 2008;112:3088\u201398.","journal-title":"Blood"},{"key":"2174_CR26","doi-asserted-by":"publisher","first-page":"E6349","DOI":"10.1073\/pnas.1510043112","volume":"112","author":"BH Phang","year":"2015","unstructured":"Phang BH, Othman R, Bougeard G, Chia RH, Frebourg T, Tang CL, et al. Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis. Proc Natl Acad Sci U S A. 2015;112:E6349\u201358.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2174_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3760-0","volume":"17","author":"Y Liu","year":"2017","unstructured":"Liu Y, Wang X, Ding N, et al. TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large b-cell lymphoma patients treated with CHOP. BMC Cancer. 2017;17:743.","journal-title":"BMC Cancer"},{"key":"2174_CR28","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.1182\/blood-2012-12-471722","volume":"121","author":"Y Li","year":"2013","unstructured":"Li Y, Gordon MW, Xu-Monette ZY, et al. Single nucleotide variation in the TP53 3\u2019 untranslated region in diffuse large b-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121:4529\u201340.","journal-title":"Blood"},{"key":"2174_CR29","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/ijc.30838","volume":"141","author":"T Zenz","year":"2017","unstructured":"Zenz T, Kreuz M, Fuge M, et al. TP53 mutation and survival in aggressive b cell lymphoma. Int J Cancer. 2017;141:1381\u20138.","journal-title":"Int J Cancer"},{"key":"2174_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100100","volume":"36","author":"S Mueller","year":"2023","unstructured":"Mueller S, Grote I, Bartels S, et al. p53 expression in luminal breast cancer correlates with TP53 mutation and primary endocrine resistance. Mod Pathol. 2023;36:100100.","journal-title":"Mod Pathol"},{"key":"2174_CR31","first-page":"784","volume":"38","author":"WJ Yu","year":"2017","unstructured":"Yu WJ, Cao LH, Wang JH, et al. Prognostic significance of proteins expression by immunohistochemical method in diffuse large B cell lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2017;38:784\u20138.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2174_CR32","first-page":"487","volume":"42","author":"X Yang","year":"2021","unstructured":"Yang X, Chen S, Qi Y, et al. Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2021;42:487\u201394.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2174_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-7-76","volume":"7","author":"J Warrick","year":"2012","unstructured":"Warrick J, Luo J, Robirds D, Branson J, Frater JL, Kreisel F, et al. Gastrointestinal lymphomas in a North American population: clinicopathologic features from one major Central-Midwestern United States tertiary care medical center. Diagn Pathol. 2012;7:76.","journal-title":"Diagn Pathol"},{"key":"2174_CR34","first-page":"1010","volume":"43","author":"YF Shi","year":"2022","unstructured":"Shi YF, Gao ZF, Li XH, et al. Investigation for pathological interpretation criteria and its prognostic value for P53 expression in Chinese diffuse large B-cell lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2022;43:1010\u20135.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2174_CR35","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00277-010-0945-x","volume":"89","author":"A Chatzitolios","year":"2010","unstructured":"Chatzitolios A, Venizelos I, Tripsiannis G, Anastassopoulos G, Papadopoulos N. Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin\u2019s lymphoma. Ann Hematol. 2010;89:889\u201396.","journal-title":"Ann Hematol"},{"key":"2174_CR36","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.3109\/10428194.2014.970550","volume":"56","author":"I Fiskvik","year":"2015","unstructured":"Fiskvik I, Beiske K, Delabie J, Yri O, Spetalen S, Karjalainen-Lindsberg M-L, et al. Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56:1742\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2174_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12030579","author":"E Park","year":"2022","unstructured":"Park E, Han H, Choi S-E, Park H, Woo H-Y, Jang M, et al. p53 immunohistochemistry and mutation types mismatching in high-grade serous ovarian cancer. Diagnostics (Basel). 2022. https:\/\/doi.org\/10.3390\/diagnostics12030579.","journal-title":"Diagnostics (Basel)"},{"key":"2174_CR38","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","volume":"120","author":"ZY Xu-Monette","year":"2012","unstructured":"Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120:3986\u201396.","journal-title":"Blood"},{"key":"2174_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1550207","volume":"15","author":"Y Jin","year":"2025","unstructured":"Jin Y, Wang Y, Wang L, Zhang H, Ren B, Zheng J, et al. TP53 mutation and immunohistochemical p53 expression characteristics in diffuse large B-cell lymphoma. Front Oncol. 2025;15:1550207.","journal-title":"Front Oncol"},{"key":"2174_CR40","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s00277-026-06821-8","volume":"105","author":"H Zhang","year":"2026","unstructured":"Zhang H, Zhang X, Wang J, et al. TP53 mutation predict poor prognosis in diffuse large B-cell lymphoma: a single-center study. Ann Hematol. 2026;105:66.","journal-title":"Ann Hematol"},{"key":"2174_CR41","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2004.11.004","volume":"119","author":"KP Olive","year":"2004","unstructured":"Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119:847\u201360.","journal-title":"Cell"},{"key":"2174_CR42","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2004.11.006","volume":"119","author":"GA Lang","year":"2004","unstructured":"Lang GA, Iwakuma T, Suh Y-A, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004;119:861\u201372.","journal-title":"Cell"},{"key":"2174_CR43","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang T, Su W, et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2022;13:974.","journal-title":"Cell Death Dis"},{"key":"2174_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.leukres.2008.06.022","volume":"33","author":"N Zainuddin","year":"2009","unstructured":"Zainuddin N, Berglund M, Wanders A, Ren Z-P, Amini R-M, Lindell M, et al. TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype. Leuk Res. 2009;33:60\u20136.","journal-title":"Leuk Res"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02174-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02174-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02174-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:03:27Z","timestamp":1783472607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02174-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2174"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02174-8","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained from all the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The study was approved by the Ethics Committee of Peking Union Medical College Hospital.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"253"}}